KRAS and neoplasm: SLC2A5 expression was significantly higher in tumor samples compared to normal tissues despite the status of EGFR, ALK, or KRAS. However, only EGFR status seemed to affect the abundance of SLC2A5, which was reduced in EGFR-mutated tumor samples (Fig. 7a).